WCM
ANAB icon

Westend Capital Management’s AnaptysBio ANAB Stock Holding History

Westend Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29
Closed -$653 – 238
2024
Q1 		$653 Buy
+29
New +$687 ﹤0.01% 297

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Westend Capital Management's ANAB Position: Q2 2024 in Review

Westend Capital Management sold out of AnaptysBio (ANAB) in Q2 2024, closing a stake of 29 shares — an estimated $653 sold.

Westend Capital Management first reported a position in ANAB in Q1 2024 and held it in 1 quarter. The position peaked at $653 in Q1 2024. 135 funds tracked by Wall St. Rank hold ANAB as of Q2 2024.

  • Westend Capital Management reported no remaining AnaptysBio position as of Q2 2024 after selling out during the quarter.
  • Westend Capital Management sold 29 AnaptysBio shares in Q2 2024, an estimated $653.
  • Westend Capital Management first reported a position in AnaptysBio in Q1 2024 and held it in 1 quarter.
  • Westend Capital Management's AnaptysBio position peaked at $653 in Q1 2024.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2024.

Based on Westend Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.